Vioxx: How Strong Is the Case against Merck?
The thousands of personal injury cases filed after Merck’s voluntary withdrawal of Vioxx appear difficult to prove. A large obstacle for plaintiffs is the admissibility of epidemiologic studies, which are required to prove specific causation. Pharmaceutical companies spend countless hours and resources developing and researching new drugs. Clinical research began to indicate that there may be an increase in adverse cardiovascular (“CV”) side effects associated with Vioxx. The reliability of this data and how it will work in our courts is a great concern.
Health Law and Policy | Torts
Date of this Version
Jason M. Weigand, "Vioxx: How Strong Is the Case against Merck?" (March 14, 2006). bepress Legal Series. bepress Legal Series.Working Paper 1135.